Evolution of acquired resistance in a ROS1(+) KRAS G12C(+) NSCLC through the MAPK pathway

Patients with metastatic NSCLC bearing a ROS1 gene fusion usually experience prolonged disease control with ROS1-targeting tyrosine kinase inhibitors (TKI), but significant clinical heterogeneity exists in part due to the presence of co-occurring genomic alterations. Here, we report on a patient wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Priest, Katherine, Le, Anh, Gebregzabheir, Amanuail, Nijmeh, Hala, Reis, Gregory B., Mandell, Melanie, Davies, Kurtis D., Lawrence, Carolyn, O’Donnell, Emily, Doebele, Robert C., Bao, Liming, Aisner, Dara L., Schenk, Erin L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9871013/
https://www.ncbi.nlm.nih.gov/pubmed/36690705
http://dx.doi.org/10.1038/s41698-023-00349-0

Ejemplares similares

Ejemplares similares